List of Tables
    Table 1. Benign Prostatic Hyperplasia Therapeutics Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Benign Prostatic Hyperplasia Therapeutics Market Trends
    Table 3. Benign Prostatic Hyperplasia Therapeutics Market Drivers
    Table 4. Benign Prostatic Hyperplasia Therapeutics Market Challenges
    Table 5. Benign Prostatic Hyperplasia Therapeutics Market Restraints
    Table 6. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Benign Prostatic Hyperplasia Therapeutics Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Benign Prostatic Hyperplasia Therapeutics Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Benign Prostatic Hyperplasia Therapeutics Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Benign Prostatic Hyperplasia Therapeutics Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Benign Prostatic Hyperplasia Therapeutics Revenue Share by Player, 2017-2022
    Table 13. Global Benign Prostatic Hyperplasia Therapeutics Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Benign Prostatic Hyperplasia Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia Therapeutics as of 2021)
    Table 15. Top Players of Benign Prostatic Hyperplasia Therapeutics in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Benign Prostatic Hyperplasia Therapeutics Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Benign Prostatic Hyperplasia Therapeutics Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Benign Prostatic Hyperplasia Therapeutics Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Benign Prostatic Hyperplasia Therapeutics Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Benign Prostatic Hyperplasia Therapeutics Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Benign Prostatic Hyperplasia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Benign Prostatic Hyperplasia Therapeutics Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Benign Prostatic Hyperplasia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Benign Prostatic Hyperplasia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Benign Prostatic Hyperplasia Therapeutics Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Abbott Laboratories Company Details
    Table 31. Abbott Laboratories Business Overview
    Table 32. Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product
    Table 33. Abbott Laboratories Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 34. Abbott Laboratories Recent Development
    Table 35. Allergan plc Company Details
    Table 36. Allergan plc Business Overview
    Table 37. Allergan plc Benign Prostatic Hyperplasia Therapeutics Product
    Table 38. Allergan plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 39. Allergan plc Recent Development
    Table 40. Astellas Pharma Company Details
    Table 41. Astellas Pharma Business Overview
    Table 42. Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product
    Table 43. Astellas Pharma Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 44. Astellas Pharma Recent Development
    Table 45. Boehringer Ingelheim Pharma GmbH and Co. KG Company Details
    Table 46. Boehringer Ingelheim Pharma GmbH and Co. KG Business Overview
    Table 47. Boehringer Ingelheim Pharma GmbH and Co. KG Benign Prostatic Hyperplasia Therapeutics Product
    Table 48. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 49. Boehringer Ingelheim Pharma GmbH and Co. KG Recent Development
    Table 50. Eli Lilly and Company Company Details
    Table 51. Eli Lilly and Company Business Overview
    Table 52. Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product
    Table 53. Eli Lilly and Company Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 54. Eli Lilly and Company Recent Development
    Table 55. GlaxoSmithKline plc Company Details
    Table 56. GlaxoSmithKline plc Business Overview
    Table 57. GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product
    Table 58. GlaxoSmithKline plc Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 59. GlaxoSmithKline plc Recent Development
    Table 60. Merck and Co. Company Details
    Table 61. Merck and Co. Business Overview
    Table 62. Merck and Co. Benign Prostatic Hyperplasia Therapeutics Product
    Table 63. Merck and Co. Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 64. Merck and Co. Recent Development
    Table 65. Pfizer Company Details
    Table 66. Pfizer Business Overview
    Table 67. Pfizer Benign Prostatic Hyperplasia Therapeutics Product
    Table 68. Pfizer Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 69. Pfizer Recent Development
    Table 70. Sanofi Company Details
    Table 71. Sanofi Business Overview
    Table 72. Sanofi Benign Prostatic Hyperplasia Therapeutics Product
    Table 73. Sanofi Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 74. Sanofi Recent Development
    Table 75. Teva Pharmaceutical Industries Limited Company Details
    Table 76. Teva Pharmaceutical Industries Limited Business Overview
    Table 77. Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product
    Table 78. Teva Pharmaceutical Industries Limited Revenue in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022) & (US$ Million)
    Table 79. Teva Pharmaceutical Industries Limited Recent Development
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
List of Figures
    Figure 1. Benign Prostatic Hyperplasia Therapeutics Product Picture
    Figure 2. Global Benign Prostatic Hyperplasia Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Benign Prostatic Hyperplasia Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 4. United States Benign Prostatic Hyperplasia Therapeutics Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Benign Prostatic Hyperplasia Therapeutics Market Size 2017-2028 (US$ Million)
    Figure 6. United States Benign Prostatic Hyperplasia Therapeutics Market Share in Global 2017-2028
    Figure 7. Benign Prostatic Hyperplasia Therapeutics Report Years Considered
    Figure 8. Product Picture of Alpha Blocker
    Figure 9. Product Picture of 5-Alpha Reductase Inhibitor
    Figure 10. Product Picture of Phosphodiesterase-5 Inhibitor
    Figure 11. Product Picture of Others
    Figure 12. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type in 2022 & 2028
    Figure 13. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 14. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    Figure 15. United States Benign Prostatic Hyperplasia Therapeutics Market Share by Type in 2022 & 2028
    Figure 16. United States Benign Prostatic Hyperplasia Therapeutics Market Size by Type (2017-2028) & (US$ Million)
    Figure 17. United States Benign Prostatic Hyperplasia Therapeutics Market Share by Type (2017-2028)
    Figure 18. Product Picture of Mono Drug Therapy
    Figure 19. Product Picture of Combination Drug Therapy
    Figure 20. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application in 2022 & 2028
    Figure 21. Global Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 22. Global Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    Figure 23. United States Benign Prostatic Hyperplasia Therapeutics Market Share by Application in 2022 & 2028
    Figure 24. United States Benign Prostatic Hyperplasia Therapeutics Market Size by Application (2017-2028) & (US$ Million)
    Figure 25. United States Benign Prostatic Hyperplasia Therapeutics Market Share by Application (2017-2028)
    Figure 26. North America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 27. U.S. Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 28. Canada Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Europe Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 30. Germany Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. France Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. U.K. Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. Italy Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Russia Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Asia-Pacific Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 36. China Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Japan Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. South Korea Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. India Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. Australia Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Taiwan Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Indonesia Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Thailand Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Malaysia Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Philippines Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Middle East & Africa Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 51. Turkey Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. UAE Benign Prostatic Hyperplasia Therapeutics Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Abbott Laboratories Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 55. Allergan plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 56. Astellas Pharma Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 57. Boehringer Ingelheim Pharma GmbH and Co. KG Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 58. Eli Lilly and Company Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 59. GlaxoSmithKline plc Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 60. Merck and Co. Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 61. Pfizer Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 62. Sanofi Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 63. Teva Pharmaceutical Industries Limited Revenue Growth Rate in Benign Prostatic Hyperplasia Therapeutics Business (2017-2022)
    Figure 64. Bottom-up and Top-down Approaches for This Report
    Figure 65. Data Triangulation
    Figure 66. Key Executives Interviewed